Type 2 diabetes mellitus (T2DM) is a well-known cardiovascular risk factor and a common cause of morbidity and mortality. It is well established that a direct relationship exists between the degree of glycemic control and risk of microvascular complications.
1-3 The goal of antidiabetes therapy is to maintain plasma glucose levels as close to normal as possible. The American Diabetes Association recommends a glycated hemoglobin A
1c (HbA
1c) goal of less than 7.0% (to convert to a proportion of total hemoglobin, multiply by 0.01), the level at which clinical trials have demonstrated fewer long-term microvascular and macrovascular complications.
4 However, data from the 1999-2000 National Health and Nutrition Examination Survey suggest that only 37% of patients with T2DM achieve this goal.
5